Metacort (Mometasone Furoate)

Mometasone furoate is a potent glucocorticoid that binds to intracellular glucocorticoid receptors. The drug‑receptor complex then modulates gene transcription, suppressing the production of inflammatory cytokines, chemokines, and other mediators, which leads to decreased swelling and irritation of the nasal mucosa.

The dose of Metacort is individualized by the prescribing clinician based on the patient’s age, severity of symptoms, and treatment duration. The prescriber determines the number of sprays per nostril and the total daily frequency, and patients should follow the specific instructions provided on the prescription label.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Healthcare providers generally weigh the potential benefits against any possible risks. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the use of Metacort with their physician before starting therapy.

To request Metacort, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Metacort (mometasone furoate) is a high‑potency intranasal corticosteroid with a low systemic bioavailability, similar to other agents such as fluticasone propionate and budesonide. Compared with lower‑potency options, mometasone often provides effective symptom control with once‑daily dosing, but choice of therapy depends on individual response, tolerability, and physician preference.

Metacort should be stored at room temperature, below 25 °C (77 °F). Keep the bottle in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain product stability.

Metacort is administered as a nasal spray. The patient gently shakes the bottle, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The same procedure is repeated for the other nostril if directed by the prescriber.

Serious risks, although uncommon, include adrenal suppression with prolonged high‑dose use, cataracts or glaucoma, severe allergic reactions such as anaphylaxis, and nasal septum perforation. Patients should report any unusual symptoms, such as persistent nosebleeds, visual changes, or signs of systemic steroid effects, to their healthcare provider promptly.

Metacort should not be used by individuals with a known hypersensitivity to mometasone furoate or any excipients in the formulation. It is also contraindicated in patients with active untreated fungal, viral, or bacterial infections of the nasal passages until the infection has been adequately treated.